Working... Menu
Trial record 1 of 2 for:    Quercetin | Idiopathic Pulmonary Fibrosis
Previous Study | Return to List | Next Study

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02874989
Recruitment Status : Recruiting
First Posted : August 22, 2016
Last Update Posted : December 13, 2018
Mayo Clinic
The University of Texas Health Science Center at San Antonio
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
The purpose of this study is to determine whether dasatinib and quercetin can reduce the expression of pro-inflammatory cells obtained by skin biopsy.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis (IPF) Drug: Dasatinib + Quercetin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis
Study Start Date : August 2016
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Arm Intervention/treatment
Experimental: Dasatinib + Quercetin Drug: Dasatinib + Quercetin

Primary Outcome Measures :
  1. Reduction in the % of pro-inflammatory expressing cells [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men between ages 50 and above, at the time of signing the informed consent.
  2. Post-menopausal women ages 50 and above, at the time of signing the informed consent. Note: Postmenopausal is defined as 12 months of spontaneous amenorrhea determined by self-report.
  3. A clinical diagnosis of IPF and characteristic chest HRCT scan (determined by panel of pulmonary radiologists) OR biopsy showing usual interstitial pneumonia (UIP).
  4. Body Mass Index (BMI) within the range 19 - 39.9 kg/ m2 (inclusive), where BMI = (weight in kg) / (height in meters)2 .
  5. Subjects participating in an exercise program must be willing to maintain their current activity level for the duration of the study period.
  6. Patients on stable therapy with nintedanib (Ofev) or pirfenidone (Esbriet) over the past 3 months.ORPatients not taking nintedanib (Ofev) or pirfenidone (Esbriet) may be enrolled if they have previously not tolerated one of those medications or if those medications have not yet been prescribed or used by the patient.
  7. Giving signed informed consent.
  8. No plans to travel over the next 6 weeks.

Exclusion Criteria:

  1. More than two moderate/severe IPF exacerbations within the past year Exacerbation is defined as worsening of two or more of the following major symptoms: dyspnea, sputum volume, sputum purulence OR worsening of any one major symptom together with at least one of the following additional symptoms: sore throat, colds (nasal discharge and/or nasal congestion), fever > 37.5 ° C without any explained cause, increased cough, increase wheeze.

    A moderate exacerbation is defined as an event that is associated with a new prescription for antibiotics and/or oral steroids. A severe exacerbation is defined as an event that is associated with hospitalization or emergency room visit.

  2. Any moderate/severe IPF exacerbation within the past 4 weeks.
  3. History of a lung transplant.
  4. Use of anti-arrhythmic medications known to cause QTc prolongation.
  5. Pulmonary hypertension or cor pulmonale confirmed by echocardiography or heart catheterization.
  6. Myocardial infarction, angina, hospitalization for cardiac aetiology, stroke or transient ischemic attack in the past 6 months.
  7. Chronic heart failure.
  8. Neurologic, musculoskeletal, or other condition that in the opinion of the study physician limits subject's ability to complete study physical assessments.
  9. Uncontrolled diabetes (HbA1c > 8% and fasting glucose >200 mg/dL or the current use of insulin).
  10. Subjects with values outside the specified ranges for the following Key Clinical Laboratory Tests must be excluded from the study:

    Renal function: Glomerular Filtration Rate (GFR) <30 (mL/min/1.73 m2) using formulae provided in the Study Reference Manual (SRM). Note: Subjects receiving dialysis are excluded from this study.

    ALT >2xULN and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

  11. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  12. QTcB or QTcF > 450 msec or QTc > 480 msec in subjects with Bundle Branch Block based on a single ECG.
  13. Subjects with a history of malignancy that is not in complete remission for at least 2 years or 1 year for non-melanoma skin carcinoma.
  14. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to participation in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  15. History of drug or alcohol abuse within 5 years prior to randomization.
  16. Use of Coumadin or other anti-platelet or anti-coagulant medication. The use of aspirin is permitted.
  17. Current use of quinolone antibiotics.
  18. Low CBC.
  19. Cognitive Impairment (MoCA score less than 21)
  20. Other medical or behavioral factors that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02874989

Layout table for location contacts
Contact: Jamie Justice, PhD 336-713-8563

Layout table for location information
United States, North Carolina
Wake Forest Baptist Health Active, not recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Texas
University of Texas Health Science Center Recruiting
San Antonio, Texas, United States, 78245
Contact: Che Kelly    210-949-3898   
Principal Investigator: Anoop Nambiar, MD         
Sponsors and Collaborators
Wake Forest University Health Sciences
Mayo Clinic
The University of Texas Health Science Center at San Antonio
Layout table for investigator information
Principal Investigator: Stephen Kritchevsky, PhD Wake Forest Univerisity Health Sciences

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences Identifier: NCT02874989     History of Changes
Other Study ID Numbers: IRB00037000
First Posted: August 22, 2016    Key Record Dates
Last Update Posted: December 13, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs